Wall Street brokerages expect Crispr Therapeutics AG (NASDAQ:CRSP) to announce earnings of $0.04 per share for the current quarter, according to Zacks. Three analysts have made estimates for Crispr Therapeutics’ earnings, with the lowest EPS estimate coming in at $0.01 and the highest estimate coming in at $0.07. Crispr Therapeutics posted earnings of ($0.92) per share during the same quarter last year, which indicates a positive year over year growth rate of 104.3%. The business is scheduled to issue its next earnings report on Monday, February 24th.

According to Zacks, analysts expect that Crispr Therapeutics will report full-year earnings of $0.65 per share for the current financial year, with EPS estimates ranging from $0.59 to $0.71. For the next year, analysts expect that the business will post earnings of ($4.65) per share, with EPS estimates ranging from ($5.38) to ($3.77). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research firms that that provide coverage for Crispr Therapeutics.

Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Monday, October 28th. The company reported $2.40 earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.95) by $3.35. The firm had revenue of $211.93 million during the quarter, compared to the consensus estimate of $6.32 million. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%.

A number of research analysts have weighed in on CRSP shares. William Blair upgraded Crispr Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, November 19th. BidaskClub downgraded Crispr Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday. TheStreet upgraded Crispr Therapeutics from a “d” rating to a “c” rating in a research note on Monday, October 28th. Roth Capital lifted their target price on Crispr Therapeutics from $65.00 to $100.00 in a research note on Tuesday, November 19th. Finally, ValuEngine downgraded Crispr Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, January 3rd. Three analysts have rated the stock with a sell rating, one has assigned a hold rating and twelve have assigned a buy rating to the company. Crispr Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $75.95.

CRSP stock traded down $1.82 during mid-day trading on Thursday, reaching $56.57. The company had a trading volume of 1,032,126 shares, compared to its average volume of 1,104,019. The company has a debt-to-equity ratio of 0.06, a current ratio of 8.32 and a quick ratio of 8.32. The stock has a 50 day simple moving average of $63.51 and a two-hundred day simple moving average of $52.46. The company has a market capitalization of $3.21 billion, a price-to-earnings ratio of -122.98 and a beta of 3.20. Crispr Therapeutics has a 52 week low of $29.34 and a 52 week high of $74.00.

In other news, Director Pablo J. Cagnoni sold 7,500 shares of Crispr Therapeutics stock in a transaction that occurred on Wednesday, October 30th. The stock was sold at an average price of $52.00, for a total transaction of $390,000.00. Following the completion of the transaction, the director now directly owns 7,500 shares in the company, valued at approximately $390,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, President Rodger Novak sold 33,618 shares of Crispr Therapeutics stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the transaction, the president now owns 33,618 shares of the company’s stock, valued at $2,353,260. The disclosure for this sale can be found here. Insiders have sold a total of 56,118 shares of company stock valued at $3,620,760 over the last quarter. 21.40% of the stock is currently owned by corporate insiders.

Hedge funds and other institutional investors have recently modified their holdings of the company. Balyasny Asset Management LLC acquired a new stake in Crispr Therapeutics during the 2nd quarter worth approximately $5,165,000. Webster Bank N. A. acquired a new stake in Crispr Therapeutics during the 4th quarter worth approximately $26,000. State Street Corp lifted its holdings in Crispr Therapeutics by 2.1% during the 3rd quarter. State Street Corp now owns 37,103 shares of the company’s stock worth $1,521,000 after purchasing an additional 758 shares during the last quarter. Millennium Management LLC acquired a new stake in Crispr Therapeutics during the 3rd quarter worth approximately $4,366,000. Finally, Bank of New York Mellon Corp lifted its holdings in Crispr Therapeutics by 116.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 33,091 shares of the company’s stock worth $1,559,000 after purchasing an additional 17,810 shares during the last quarter. Institutional investors own 49.83% of the company’s stock.

About Crispr Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Recommended Story: What is a balanced fund?

Get a free copy of the Zacks research report on Crispr Therapeutics (CRSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.